- Gilead Sciences Inc GILD has exercised its option to license Nurix Therapeutics Inc's NRIX investigational targeted protein degrader molecule NX-0479 exclusively.
- This bivalent degrader, GS-6791, is the first development candidate from the previously announced Nurix-Gilead collaboration.
- GS-6791 is a potent, selective, oral IRAK4 degrader with potential applications in rheumatoid arthritis (RA) and other inflammatory diseases.
- Under the terms of the Collaboration, Nurix will receive an option exercise payment of $20 million and potentially up to an additional $425 million in milestone payments, as well as up to low double-digit tiered royalties on product net sales.
- In June 2019, Gilead and Nurix entered a global strategic collaboration to discover, develop and commercialize a pipeline of up to five innovative targeted protein degradation therapies for patients with cancer and other challenging diseases.
- Under the terms of the agreement, Nurix received an upfront payment of $45 million and is eligible to receive up to approximately $2.3 billion in total additional milestone payments.
- Nurix will retain the option to co-develop and co-detail up to two programs in the U.S.
- For those programs, Nurix opts in to co-develop and co-detail, the parties will split development costs, profits, and losses 50/50 for the United States. Nurix will be eligible to receive royalties on ex-U.S. sales and reduced milestone payments.
- Gilead has the right to veto up to one co-development option, which will revert back to Nurix for use on potential future licensed products.
- Price Action: GILD shares are up 2.35% at $79.13 on the last check Monday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
